Immunologic and molecular analysis of diffuse large B-cell lymphoma

我们分析差异large B-cell lymphoma (DLBCL) using hitologic，immunologic and molecular technique. A total of 120 cases of DLBCL examined comprised 83 cases ofcentroblastic variant （CB）T-cell or histiocyte rich variant (TCHR). Immunologic profiles of our series was as follows：CD5-positive cases/examined casescb12 /83, ib0 /12， alb0 /18和TCHR 0/7， CD 10-positive cases/ examined cases；cb8 /83, ib1 /12, alb0 /18 and TCHR 0/7, and bcl 6-positive cases/examined cases；cb55 /67, ib5 /6，ALB 3/10 and 1/6 in TCHR. Infection of Epstein Barr Virus (EBV) was performed using EBER-1 RNA in TCHRsitu hybridization. EBV was harbored in the lymphoma cells of 5/82 in CB, 0/12 in IB，6/18 in ALB and 1/6 in TCHR. The distribution of somatic mutation of immunoglobulin heavy chain genevariable region was ranged 0.7-12.9% with an average of 6.2% in CD5 - D1CB + D1CB (10 cases)，2.0-25.9% with an average of 11.1% in CD5 - D1CB (29 cases)，5.4-30.2% with an average of 13.5% in IB (3 cases)，0-12.5% with an average of 8.2% in ALB (9 cases) and 6.8-17.0% with an average of 10.7% in ALB (4)The mRNA of β-actin, CD10, PAX-5，RAG-1和alkaline phosphatase were amplified by RT-PCR. The RT-PCR产品were found in 14/14（β-actin）， 2/14 (CD10), 3/14(px -5)，3/14（RAG-1）和0/14(alkaline phosphatase).这些数据indicated that the histogenesis ofCD5-positive DLBCL was different from that of CD5-negative DLBCL belonged to the neoplasms of B2cells. The clinical outcome of cd -positive DLBCL was worse than that of cd -negative DLBCL.CD5-negative DLBCL may still involve various kinds of DLBCL，such as transformed DLBCL from follicular lymphoma and DLBCL with differentiation to plasma cells。

We analyzed diffuse large B-cell lymphoma (DLBCL) using hitologic, immunologic and molecular technique. A total of 120 cases of DLBCL examined comprised 83 cases of centroblastic variant (CB), T-cell or histiocyte rich variant (TCHR). Immunologic profiles of our series was as follows: CD5-positive cases/examined cases; CB 12/83, IB 0/12, ALB 0/18 and TCHR 0/7, CD 10-positive cases/ examined cases; CB 8/83, IB 1/12, ALB 0/18 and TCHR 0/7, and bcl 6-positive cases/examined cases; CB 55/67, IB 5/6, ALB 3/10 and 1/6 in TCHR. Infection of Epstein Barr Virus (EBV) was performed using EBER-1 RNA in situ hybridization. EBV was harbored in the lymphoma cells of 5/82 in CB, 0/12 in IB, 6/18 in ALB and 1/6 in TCHR. The distribution of somatic mutation of immunoglobulin heavy chain gene variable region was ranged 0.7-12.9% with an average of 6.2% in CD5ィイD1+ィエD1CB (10 cases), 2.0-25.9% with an average of 11.1% in CD5ィイD1-ィエD1CB (29 cases), 5.4-30.2% with an average of 13.5% in IB (3 cases), 0-12.5% with an average of 8.2% in ALB (9 cases) and 6.8-17.0% with an average of 10.7% in ALB (4 cases). The mRNA of β-actin, CD10, PAX-5, RAG-1 and alkaline phosphatase were amplified by RT-PCR. The RT-PCR products were found in 14/14 (β-actin), 2/14 (CD10), 3/14(PAX-5), 3/14(RAG-1) and 0/14(alkaline phosphatase). These data indicated that the histogenesis of CD5-positive DLBCL was different from that of CD5-negative DLBCL belonged to the neoplasms of B2 cells. The clinical outcome of CD5-positive DLBCL was worse than that of CD5-negative DLBCL. CD5-negative DLBCL may still involve various kinds of DLBCL, such as transformed DLBCL from follicular lymphoma and DLBCL with differentiation to plasma cells.